Bristol drug shows promise against melanoma tumors in brain

05/23/2010 | Reuters

Researchers found that Bristol-Myers Squibb's experimental cancer drug ipilimumab had no serious side effects in patients whose skin cancer had spread to the brain. Four of 51 patients in a midstage trial had a partial response to ipilimumab, while the drug stabilized brain and other tumors in five of 51 patients, the researchers said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY